BrainsWay to Present at the Sidoti December Micro-Cap Investor Conference
BURLINGTON, Mass. and JERUSALEM, Nov. 30, 2021 – BrainsWay (NASDAQ: BWAY), a leader in noninvasive neurostimulation treatments for mental health disorders, announced that CEO Christopher von Jako, Ph.D., will present at the Sidoti December Micro-Cap Investor Conference on December 9, 2021, at 10 am EST. The event, occurring December 8-9, will also feature one-on-one investor meetings. BrainsWay's Deep TMS technology is FDA-cleared for major depressive disorder, OCD, and smoking addiction. For more details, visit www.brainsway.com.
- None.
- None.
BURLINGTON, Mass. and JERUSALEM, Nov. 30, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present and participate in one-on-one investor meetings at the Sidoti December Micro-Cap Investor Conference.
Event: Sidoti December Virtual Micro-Cap Investor Conference
Date: December 8-9, 2021
Presentation: December 9, 2021, at 10 am EST
Webcast: https://sidoti.zoom.us/webinar/register/WN_VPWAO69rSE6J1Tp9kGmQVw
Management will also meet with investors during the event. Investors interested in meeting with the BrainsWay management team during the conference should contact their Sidoti representative.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
Contacts:
Scott Areglado
SVP and Chief Financial Officer
617-771-2287
SAreglado@brainsway.com
Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com
FAQ
What is the date of the Sidoti December Micro-Cap Investor Conference for BWAY?
When will BrainsWay's presentation occur during the Sidoti Conference?
Who is presenting for BrainsWay at the Sidoti Conference?
What is BrainsWay known for in the mental health sector?
What FDA-cleared indications does BrainsWay have?
